Skip to main content
. 2017 Aug 1;10(8):9001–9011.

Figure 5.

Figure 5

CHRFAM7A suppresses the p38/JNK pathway. (A) Western blot analysis (upper) and quantification (lower) of p38, Akt (B), Erk (C) and JNK (D) phosphorylation in irradiation-injured lacrimal glands. The results demonstrate the effects of administering hNSG + RT, hNSG + RT + CHRFAM7A, hNSG + RT + CHRFAM7A + siRNA, and hNSG + RT + CHRFAM7A + p38 inhibitor (SB203580, a p38 MAPK inhibitor with an IC50 of 0.3-0.5 μM) on p38 phosphorylation in irradiation-injured lacrimal glands. Lacrimal injury was induced in mice that received radiotherapy. The data are shown as the mean ± SD of five independent experiments. In (A), (B) and (D), *P<0.05 vs. hNSG, hNSG + RT + CHRFAM7A, hNSG + RT + CHRFAM7A + SB203580 (hNSG: non-irradiated humanized mice; hNSG + RT: radiotherapy-treated humanized mice; hNSG + RT + CHRFAM7A: radiotherapy-treated humanized mice after CHRFAM7A transfection; hNSG + RT + CHRFAM7A + siRNA: radiotherapy after CHRFAM7A and siRNA transfection; hNSG + RT + CHRFAM7A + SB203580: radiotherapy humanized mice after CHRFAM7A transfection and the administration of SB203580).